At NextPharma, our priority is to invest in our infrastructure so that we can meet your needs even better.
We are pleased to announce that an investment of €8.8 million, partly supported by the French government’s France 2030 plan, has been made at our Limay site.
This investment will enable the Limay site to double its production capacity to more than 75 million sales units per year and will include a new manufacturing area dedicated to non-sterile liquids, enabling the production of essential medicines such as Levetiracetam. The new facilities, equipped with advanced technology, will also be able to produce 22 additional essential medicines.
This investment is part of our commitment to a sustainable approach, in line with our carbon-neutral objectives.
As a CDMO, our mission is to offer you reliable development and manufacturing solutions. We are also proud to contribute to the relocation of essential production in Europe, ensuring better availability of treatments for patients.
A big thank you to you, our partners, for your trust, and to all the people who make this success possible!
